Adrina Kalasho Kuzmiszyn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adrina Kalasho Kuzmiszyn has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Anders Lund Selli
Department of Medical Biology, Experimental and Clinical Pharmacology, UiT – The Arctic University of Norway, Tromsø, Norway
1 shared publication - Erik Sveberg Dietrichs
Experimental and Clinical Pharmacology Research Group, Department of Medical Biology, UiT, The Arctic University of Norway, 9037 Tromsø, Norway; Department of Clinical Pharmacology, Division of Diagnostic Services, University Hospital of North Norway, 9038 Tromsø, Norway
1 shared publication - Georg Sager
Department of Medical Biology, Faculty of Health Sciences, The Arctic University of Norway, Tromsø, Norway
1 shared publication - Natalia Smaglyukova
Department of Medical Biology, Experimental and Clinical Pharmacology, UiT – The Arctic University of Norway, Tromsø, Norway
1 shared publication - Ole Martin Fuskevåg
University Hospital of North Norway, Division of Diagnostic Services, Tromsø, Norway
1 shared publication - Timofei Kondratiev
Anesthesia and Critical Care Research Group, Department of Clinical Medicine, UiT, The Arctic University of Norway, 9037 Tromsø, Norway
1 shared publication
Latest Publications
- Open Access
- 15 December 2022
- Published by Springer Nature in Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine
- Vol. 30 (1) , 1-10
Pharmacodynamic properties for inhibition of cAMP- and cGMP elimination by pentoxifylline remain unaltered in vitro during hypothermia
Background: Rewarming from hypothermia is associated with severe complications, one of which is hypothermia-induced cardiac dysfunction. This condition is characterized by decreased cardiac output accompanied by increased total peripheral resistance. This contributes to mortality rate approaching 40%. Despite this, no pharmacological interventions are recommended for these patients below 30 °C. Raising the intracellular levels of cAMP and/or cGMP, through PDE3- and PDE5-inhibitors respectively, have showed the ability to alleviate hypothermia-induced cardiac dysfunction in vivo. Drugs that raise levels of both cAMP and cGMP could therefore prove beneficial in patients suffering from hypothermia-induced cardiac dysfunction. Methods: The unselective PDE-inhibitor pentoxifylline was investigated to determine its ability to reach the intracellular space, inhibit PDE3 and PDE5 and inhibit cellular efflux of cAMP and cGMP at temperatures 37, 34, 30, 28, 24 and 20 °C. Recombinant human PDE-enzymes and human erythrocytes were used in the experiments. IC50-values were calculated at all temperatures to determine temperature-dependent changes. Results: At 20 °C, the IC50-value for PDE5-mediated enzymatic breakdown of cGMP was significantly increased compared to normothermia (IC50: 39.4 µM ± 10.9 µM vs. 7.70 µM ± 0.265 µM, p-value = 0.011). No other significant changes in IC50-values were observed during hypothermia. Conclusions: This study shows that pentoxifylline has minimal temperature-dependent pharmacodynamic changes, and that it can inhibit elimination of both cAMP and cGMP at low temperatures. This can potentially be effective treatment of hypothermia-induced cardiac dysfunction. Trial registration: Not applicable.
- 15 December 2022
- Published by Springer Nature in Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine
- Vol. 30 (1) , 1-10
Open AccessPharmacodynamic properties for inhibition of cAMP- and cGMP elimination by pentoxifylline remain unaltered in vitro during hypothermia
Background: Rewarming from hypothermia is associated with severe complications, one of which is hypothermia-induced cardiac dysfunction. This condition is characterized by decreased cardiac output accompanied by increased total peripheral resistance. This contributes to mortality rate approaching 40%. Despite this, no pharmacological interventions are recommended for these patients below 30 °C. Raising the intracellular levels of cAMP and/or cGMP, through PDE3- and PDE5-inhibitors respectively, have showed the ability to alleviate hypothermia-induced cardiac dysfunction in vivo. Drugs that raise levels of both cAMP and cGMP could therefore prove beneficial in patients suffering from hypothermia-induced cardiac dysfunction. Methods: The unselective PDE-inhibitor pentoxifylline was investigated to determine its ability to reach the intracellular space, inhibit PDE3 and PDE5 and inhibit cellular efflux of cAMP and cGMP at temperatures 37, 34, 30, 28, 24 and 20 °C. Recombinant human PDE-enzymes and human erythrocytes were used in the experiments. IC50-values were calculated at all temperatures to determine temperature-dependent changes. Results: At 20 °C, the IC50-value for PDE5-mediated enzymatic breakdown of cGMP was significantly increased compared to normothermia (IC50: 39.4 µM ± 10.9 µM vs. 7.70 µM ± 0.265 µM, p-value = 0.011). No other significant changes in IC50-values were observed during hypothermia. Conclusions: This study shows that pentoxifylline has minimal temperature-dependent pharmacodynamic changes, and that it can inhibit elimination of both cAMP and cGMP at low temperatures. This can potentially be effective treatment of hypothermia-induced cardiac dysfunction. Trial registration: Not applicable.